Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...

In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...